Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That should be around 1500 shares then.
Investors generally want their stocks to perform.
Thanks Matagordaville and everyone for posting. On the face of it it looks as if the science is too big for the company. Much could happen here including an offer. Anybody else see that? All in all the progression is great with plenty more to come.
Today I am giving to those that went to the meeting as their input is likely to be far more valuable than the usuals on here.
I am very grateful for any news and will let those who are there cast judgement if they want.
The 18th I think and I hope the Judge chucks the suit out.
I want our lawyers to decimate him and his accomplices!
Aside from that the stock is unbelievably cheap.
I totally agree. Eventually they will lose their shirts (hopefully).
I see someone is trying to rain on our parade today. Everything from the company screams buy but the disconnect continues.
Good morning to you Youssef and fellow I Hubers and I look forward to everyone's comments.
I thought today's news was very good and I expect we may get a few tippets from the SH Meeting tomorrow but most of all I would like to be rid of the lawyers.
For AM 17 the story should be "the science and drug potential will easily take this over $2 when it will uplist and soar to new highs."
In my opinion we would have fully recovered from the Mako attack if it had not been for the threat of a shareholder lawsuit by Rosen which self fulfilled the shareholder losses and at the same time profited Mako.
Boy am I angry.
We have the ridiculous and frivolous potential lawsuit hanging over us which, in my opinion, is causing great damage to our share value and damage to our reputation.
This needs to go away.
Who says we aren't? Leo has told us there are eyes on us and I definitely think it will happen.
If the Rosen suit can be eliminated today's news update should attract new investors as how can you not take a chance on a bio-tech with all of CTIX's promise?
Everything you want a bio-tech to be~~ongoing trials, new trials being planned, diversified pipeline and progression of the science for a very exciting future.
I agree lots of fantastic things happening and great progress being made by the company.
I absolutely don't see how rushing a trial at Dana-Farber would be a good move. The data is compelling and any chance to continue trialling with Dana-Farber can only be good. Tremendous potential in Brlacidin and the pipeline looks great.
I certainly think you have implied it on many an occasion and another thing the uplist will happen when it happens and your $4 price is by no means current thinking.
What I am really saying is I think it is complete nonsense that buyers at today's price will have to wait 3-5 years for appreciation. The stock is cheap (very) and is backed up by excellent progress to put on the market a novel mechanism of antibiotic which is not subject to resistance. Then you have Kevetrin P1 at Dana Farber announcing successful conclusion of Phase 1 any moment now. That will be closely watched by many interested parties. Lastly, Plurisol trial results due end of 1st Qtr 2016. I didn't forget B-OM but we may know a little more on Tuesday.
Although drug progression may take 3-5 years, current value and future potential value for the drugs and partnerships will take this stock much higher and much quicker than the 3-5 year drug progression itself. Right now the stock has been discounted to failure level when all the scientific evidence announced so far points to success. It's grossly undervalued.
I blame myself for chasing the stock higher but thought the good news from Brilacidin and the potential from Kevetrin would keep the price both up and topical enough to keep the investing public interested. The news has only got better yet the price is where it is. Well, if it looked cheap at $4.50 it’s looks really good down here. Back at $4.50 there were no negatives then along came a news gap and Mako. The courts should take care of Mako and the news is only getting more exciting with a fantastic chance for a really good pop to the upside. So I am not beating myself up for the decisions I made and am just as excited today as I was when the price was higher. The company has continued to make excellent progress and in my opinion added a lot of value to the stock. I do believe we will see big pharma interested in our entire pipeline which will add many $s to our share price. With all the good news I do not believe we will see the stock down here much longer.
Continued good trial results will bring big pharma,investors and all. No waiting for years that's total bull.
I agree but good luck getting everyone else to agree. CTIX gets attacked every day but if the drugs work and can be approved the stock wins.
Much higher up volume to down volume, maybe another turn to the upside before the close.
Unloved, undervalued all about to change. Go $CTIX
Any day we could get traction.
I like looking at unfiltered possibilities and can then make my own assessment of time lines. Investing requires an open mind as nothing about it is cut and dry. CTIX has boundless possibilities some of which are near term and others long term. In my view this bio-tech offers incredible potential for appreciation and is waiting to be discovered by the investing community.
Hope he/she is right gov. Based on B going to a P3 and Ks P53 activation and ovarian cancer P2 coming up the stock is incredibly cheap. It's a typical volatile bio-tech with plenty of catalysts to catch it on fire. Not forgetting P could be one of them.
We are still governed by DF for the official end of P1. To my knowledge the P1 has the chance to be amazing and there is a lot of hope that once released the P2s will be go as fast as Leo can make them. Right now we just have to wait but luckily there is a very potent pipeline here that at any time could attract interested parties. As I said yesterday the cogs are turning but the wheels aren't.
No it's not. The cogs are turning but the wheels aren't. It will all happen way before your projections.
For the lay people on here (that's me) it's hard to understand that when you use the word "fail" in clinical trial terms you don't actually mean it. Little wonder it causes so much controversy.
The value of CTIX stock is subject to a re-rating anytime. So shorting is a very bad idea for retail investors. This bio-tech is unloved at present but given it's stellar pipeline, upcoming news and events I expect the love to return. The best way to play it is to remain patient. All bio-techs are risky but offer very high returns if successful.
Thank you BK it is a pleasure to read your posts.
I suppose it also means that the orphan drug designation is just for safety and effectiveness doesn't count. Not what it says below:
The Orphan Drug Designation program provides orphan status to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S., or that affect more than 200,000 persons but are not expected to recover the costs of developing and marketing a treatment drug.
Read the following:
“This is great news that the tenth cohort has been completed, once again demonstrating the safety of Kevetrin. Our team is excited by the fact that no dose limiting toxicity (DLT) has been seen even at these higher levels, as DLT has historically been a significant hurdle for any biotech targeting p53. As such, we’re going to continue to push our novel drug as far as possible for maximum therapeutic effect and to collect the most robust data set possible,” commented Dr. James Alexander, Chief Operating Officer at Cellceutix. “We have seen some encouraging data in different types of cancer to date and the eleventh cohort gives us the opportunity to add to our knowledge base in preparation for future clinical studies.” - See more at: http://cellceutix.com/tenth-cohort-completed-in-cellceutix-clinical-trial-of-anti-cancer-drug-kevetrin-no-adverse-events-reported/#sthash.ZCVrrzfv.dpuf
I think it would be very helpful if you would qualify the comments you make in your post and say that although there have been insinuations you yourself don't believe them to be true.
If you don't we might be forgiven for thinking otherwise.
I think your opinion is spot on. The Dana Farber release of news on Phase 1 I believe will provide that third party endorsement we seem to need to get this going. Then, in my opinion, we will start to get noticed by industry analysts, media, investment gurus etc., and it could happen very quickly and be very rewarding.
And for he (Rosen) knowing the research he relied on has little to no veracity in it he is certainly brazen.
As you rightly say it is a gift at these prices. The news has all been good and once the threat of Rosen is lifted (if not before) so is the price.